Primary Prevention
Statin use for primary prevention substantially lower among Black, Hispanic adults
Among adults with an indication for statin therapy for primary prevention, there are marked disparities in statin use by race and ethnicity groups, with the lowest use rates among Black and Hispanic adults, cross-sectional data show.
ACC joins with World Congress of Cardiology to highlight breaking CV science
The 2023 American College of Cardiology Scientific Session will be held live in New Orleans from Saturday to Monday and virtually, with 43 late-breaking trials and featured clinical research presentations.
Aspirin may not lower risk for first CV event in those with family history of premature MI
In people with a family history of parental premature MI, aspirin for primary prevention was not associated with reduced CV events or overall mortality, according to data published in the European Journal of Preventive Cardiology.
Addition of sleep metric in updated Life’s Essential 8 predicts CVD incidence
The incorporation of sleep as a CV health metric, as recently done with the American Heart Association’s updated Life’s Essential 8 risk calculator, may enhance CVD primordial and primary prevention efforts, data show.
VIDEO: Updated USPSTF statin guidelines can help PCPs prevent CVD
In August, the U.S. Preventive Services Task Force released a new recommendation statement on the use of statin therapy for primary prevention of CVD. Like its 2016 guidelines, the USPSTF recommended statins as primary prevention for adults aged 40 to 75 years with at least one CVD risk factor and a 10% or greater 10-year risk for CVD.
‘Similar strategy’ needed for global CVD prevention in men, women: PURE
The magnitude of associations with major CVD for most risk factors are similar in women and men, despite sex differences in risk factor levels, according to an analysis of the PURE study.
ESC: Primary prevention, management of CV issues important in patients with cancer
The European Society of Cardiology task force on cardio-oncology has issued its inaugural guideline for the prevention and management of cardiotoxicity before, during and after adult patients are treated with anticancer therapies.
USPSTF statin recommendations for primary prevention mostly unchanged since 2016
The U.S. Preventive Services Task Force’s new recommendation statement on the use of statin therapy for primary prevention in adults aged 40 to 75 years with no history of CVD is similar to its 2016 recommendations.
Better primary, secondary prevention needed to reduce prehospital MI death
Prehospital deaths are a larger contributor to MI mortality, and how it varies within and across high-income countries, than hospital case fatality, highlighting a need for more early intervention efforts, data show.
Statin use for CVD may lower risk for COVID-19 hospitalizations, deaths
Statin use for primary prevention of CVD was associated with lower risk for COVID-19 hospitalizations and in-hospital deaths, according to findings from a cohort study published in the Journal of the American Heart Association.